Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups

[1]  Peter Devilee,et al.  High‐throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium , 2016, The journal of pathology. Clinical research.

[2]  S. Barni,et al.  Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients , 2015, Breast Cancer Research and Treatment.

[3]  F. André,et al.  Ki67—no evidence for its use in node-positive breast cancer , 2015, Nature Reviews Clinical Oncology.

[4]  Päivi Heikkilä,et al.  Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium , 2014, The journal of pathology. Clinical research.

[5]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Carsten Denkert,et al.  Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study , 2014, Clinical Cancer Research.

[7]  R. Greil,et al.  The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer , 2014, Clinical Cancer Research.

[8]  Arvydas Laurinavicius,et al.  A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue , 2014, Breast Cancer Research.

[9]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[10]  H. Tsuda,et al.  Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study , 2013, Cancer science.

[11]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  F. Zeman,et al.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.

[13]  Anais Malpica,et al.  Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer , 2012, Histopathology.

[14]  M. Dowsett,et al.  Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  S. Cross,et al.  PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 , 2012, British Journal of Cancer.

[16]  P. Dzięgiel,et al.  Tissue microarray technique in evaluation of proliferative activity in invasive ductal breast cancer. , 2012, Anticancer research.

[17]  D C McMillan,et al.  Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer , 2012, British Journal of Cancer.

[18]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[19]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E Leonardi,et al.  Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies , 2011, Diagnostic pathology.

[21]  W. Han,et al.  Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis , 2011, Breast Cancer Research.

[22]  F M Blows,et al.  Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer , 2011, British Journal of Cancer.

[23]  Mikael Lundin,et al.  Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer , 2011, BMC clinical pathology.

[24]  Vilppu J Tuominen,et al.  ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.

[25]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[26]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[27]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[28]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Kosma,et al.  The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[30]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[31]  I. Ellis,et al.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. , 1995, British Journal of Cancer.